Pila Pharma AB is a Sweden-based clinical stage pharmaceutical company, active in the biotechnology sector. The Company conducts clinical tests in phase 2 with drugs against type 2 diabetes. The target product is a tablet that is taken orally in an early stage of diabetes to restore the body's insulin production and thereby reduce the patient's blood sugar level. PILA PHARMA's patent-protected product candidate is called XEN-D0501 and is a TRPV1 antagonist, a novel type of oral anti-diabetic agent for treatment of type 2 diabetes. Pila Pharma AB has completed two phase 2a clinical trials (PP-CT01 and PP-CT02), that both demonstrated that XEN-D0501 is well tolerated by people with type 2 diabetes. In addition, the product is expected to have fewer unwanted side effects than alternative forms of treatment.
Metrics to compare | PILA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPILAPeersSector | |
---|---|---|---|---|
P/E Ratio | −15.7x | −5.0x | −0.7x | |
PEG Ratio | −0.23 | −0.11 | 0.00 | |
Price/Book | 42.2x | 3.8x | 2.6x | |
Price / LTM Sales | 103.7x | 13.8x | 3.2x | |
Upside (Analyst Target) | - | 55.9% | 47.0% | |
Fair Value Upside | Unlock | −4.1% | 7.5% | Unlock |